Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amit Govil

Nephrology Cincinnati, OH Medical Doctor

NPI 1447208566 CMS profile 110866

231 Albert Sabin Way, Ml0585, Cincinnati, OH 45267

Open in the dashboard

General payments

$298,288

312 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$145,824 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Amit Govil of Cincinnati, OH is reported in the CMS Open Payments database as having received $298,288 across 312 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $145,824 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $59,618 67
2024 General $21,419 29
2023 General $21,020 26
2022 General $81,151 75
2021 General $32,381 23
2020 General $22,576 14
2019 General $60,124 78

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amit Govil
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Amit Govil were reported at $59,618. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Amit Govil Nephrology median Middle half National median
2019 $60,124 $236 $90–$588 $163
2020 $22,576 $135 $46–$364 $114
2021 $32,381 $202 $67–$551 $132
2022 $81,151 $242 $77–$695 $149
2023 $21,020 $254 $84–$766 $160
2024 $21,419 $300 $99–$852 $164
2025 $59,618 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Mallinckrodt Hospital Products Inc. $154,260 132 payments
  2. Mallinckrodt Enterprises LLC $58,250 72 payments
  3. Veloxis Pharmaceuticals, Inc. $44,048 39 payments
  4. Amgen Inc. $16,720 25 payments
  5. Novartis Pharmaceuticals Corporation $8,707 6 payments
  6. Vertex Pharmaceuticals Incorporated $6,840 5 payments
  7. Akebia Therapeutics Inc $6,341 12 payments
  8. ANI Pharmaceuticals, Inc. $2,062 6 payments
  9. Relypsa, Inc. $235 2 payments
  10. NxStage Medical, Inc. $185 2 payments
  11. Other $640 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $201,378 58 payments
  2. Consulting Fee $57,274 24 payments
  3. Travel and Lodging $21,218 97 payments
  4. Honoraria $9,925 4 payments
  5. Food and Beverage $8,321 126 payments
  6. Education $133 2 payments
  7. Gift $41 1 payment
Products named General payments · program years 2019–2025
  1. ACTHAR Immunology $148,080 129 payments
  2. ACTHAR Autoimmune And Rare Disease $58,250 72 payments
  3. Envarsus Immunosuppresant $37,322 36 payments
  4. TAVNEOS $12,001 18 payments
  5. ENVARSUS Transplantation $6,725 3 payments
  6. Vafseo $6,341 12 payments
  7. TERLIVAZ $3,795 2 payments
  8. PURIFIED CORTROPHIN GEL $2,062 6 payments
  9. Veltassa $123 1 payment
  10. NXSTAGE SYSTEM ONE $115 1 payment
  11. Other $614 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$13,547

Medicare's payments for the services billed

Medicare patients

52

Average age 59

Services billed

120

28 women, 24 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%
Ischemic heart disease 62%
Diabetes 60%
Heart failure 52%
Depression 38%
Arthritis 38%
Atrial fibrillation 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ACTHAR
  • Mallinckrodt Hospital Products Inc. $21,062
$21,062 — —
Veltassa
  • Relypsa, Inc. $112
$112 — —
TAVNEOS
  • Amgen Inc. $62
$62 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

312 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nephrology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record